Update from Amarin (AMRN) Conference Call

A few KEY Callout from today's Conference call are given below: 
  • Q1 2020 Projection: prescription levels grew and exceeded Q1 expectations. Total revenue estimated to be $150 million, with potential to be modestly higher with international and Canada. Net total revenue, 105% more than in Q1 2019!
  • Insurance coverage for Vascepa expanded by BlueCross/ANTHEM insurance in 14 states. A couple of insurance companies plans now cover Vascepa as a preferred brand.
  • Amarin is going to fight very hard on the higher Court with most reputed attorney in the business
  • Amarin plans to launch generic in case they lose the court battle in the higher court. This seems to be good idea in my view because generic manufacturer will get toasted.
  • Persistent sales effort in U.S continues by sales personal, waiting for FDA to approve the advertisement expected by June to vigorously start advertising. 
  • The company is expecting approval in Europe by end of the year. It's a huge market of over $200 Billion. Amarin also expect to get 13 years possible right in Europe. The Cost of Vascepa could be more or at least the same cost on what it's sold in U.S.
  • China is on Target before the end of the year. There is no impact of COVID-19 for China testing.
  • More importantly, PARTNERSHIP will be determined by Q3 in Europe depending on what value the partnering companies brings.
  • Due to the complex manufacturing process the generics will find it not worth the money and effort to go forward with their plans of manufacturing generic equivalent of Vascepa in near future.
  • Management is sincerely hoping that some point of time down the line, patent court case should be overturned. Even if it's not, Amarin could still generate in billions as I perceive.
Disclaimer: These are solely my own pinion that I wanted to share with my blog readers. This is not a recommendation to buy/sell. I don't advise buying/selling any equity. Please do your own due diligence before buying/selling any equity.  The above facts are to the best of my knowledge and may/may not be correct. Caution is warranted!



Comments

Popular Post

Shesa's JUN 2025 Investment Blog

Shesa's JULY 2025 Investment Blog

Shesa's Weekend Update - 6|29|25